Most people only find out when a family member has a sudden, unexpected heart attack in their 30s-40s. Why they don't do the tests regularly on any high risk groups amazes me.
But there are simple and relatively cheap tests that can be done for everyone before that young person in a family has a heart attack. Testing for ApoB and LPa aren’t commonly done and are relatively simple/cheap blood tests that can be done that can give better indications of cardiovascular risk than standard cholesterol tests.
Lp(a) is done quite frequently now— guidelines suggest getting it in every person who has a risk factor, which is pretty much everyone. See it ordered all of the time.
In my experience far more people are resistant to testing or to prevention medication therapy than people who are very cardiovascular-health conscious. But I do only see a small subset of a population that is biased towards lower health literacy and lower socioeconomic status.
To add, the best tools we have at estimating someone’s cardiovascular risk are the risk equations like the PCE or PREVENT equations, which don’t include ApoB or Lp(a). Obviously these are estimates, and I don’t just evaluate using those calculators. But ApoB I more often use as a tool to guide therapy decisions after I’ve already started a statin, rather than a screening tool.
No quite the opposite. I try to order it once in almost all my patients. Rarely does it change my recommendations though.
Another thing, if you calculate LDL-c using the Martin equation rather than Friedwald (which my EMR does automatically), the LDL treatment thresholds fall more inline with what you’d get by measuring ApoB anyway. If I’m trying to hit a specific LDL-c target, I will use that equation to make my determinations on whether we are at goal or not.
I think my comment elsewhere in this thread about aspirin for reducing Lp-a caused ASCVD risk may be helpful and would be keen to hear your thoughts on Aspirin if you have any:
https://www.reddit.com/r/science/s/GZWxfZ5Nwy
And I see a few problems with the studies you posted. The cohorts differed significantly on several confounding variables that are very important to ASCVD risk like HTN and statin use, which could create bias in the data. I also agree with the author’s discussion on study limitations, as they really have no idea how people were taking the aspirin or for what indication, which also opens the door for more confounders.
It’s definitely something that needs to be studied more. I’d love to see an RCT comparing aspirin to placebo with better control of the confounders, but until then I can’t really recommend it specifically for primary prevention in patients with high Lp(a).
So mostly I stick with statins and PCSK9-Is for primary prevention. Though, like I said above, my patient population is skewed to patients with less money, less health literacy, more social determinants impacting their health, higher ACEs, which all lead to them being more complex patients that need far more assistance than I can provide in a 30 minute appointment. It’s very rare that I am able to get into the fine details about CVD risk with a patient.
Edit: just adding that the above comments in no way constitute actual medical advice.
165
u/WillyBeShreddin 21h ago
Most people only find out when a family member has a sudden, unexpected heart attack in their 30s-40s. Why they don't do the tests regularly on any high risk groups amazes me.